Şunu aradınız:: dehiscence (İngilizce - Maltaca)

wound dehiscence
qsim tal-ġrieħi

wound dehiscence, wound secretion
tnixxija mill-ferita

uncommon: incision site pain, seroma, wound dehiscence
mhux komuni: uġigħ fil-post tal-ferita, seroma, ftuħ ta’ feriti

pazopanib should be discontinued in patients with wound dehiscence.
il-pazopanib m’għandux jitkompla jittieħed f’pazjenti b’ feriti miftuħa.

common: wound dehiscence, secretion, erythema; heterotopic bone formation, pseudarthrosis.
qsim tal- ġerħa, tnixxija, eritema, formazzjoni tal- għadam eterotopiċi, psewdartrożi.

there have been reports of impaired or delayed wound healing in patients receiving rapamune, including lymphocele and wound dehiscence.
kien hemm rapporti ta’ fejqan indebolit jew imdewwem ta’ feriti f’pazjenti li kienu qed jirċievu rapamune, li jinkludi limfosel jew ftuħ tal-ferita.

treatment with zaltrap is associated with potential for compromised wound healing (wound dehiscence, anastomotic leakage).
il-kura b’zaltrap huwa assoċjat ma’ riskju li jkun hemm fejqan mhux komplet tal-feriti (qsim tal- ferita, tnixxija anastomotika).

cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.
każijiet ta’ ftuħ anastomotiku tal-ferita kirurġika tal-bronki, il-biċċa l-kbira fatali, kienu rrappurtati f’pazjenti li kellhom trapjant tal-pulmun de novo meta sirolimus intuża bħala parti minn kors immunosoppressiv.

seroma, excessive licking of incision area, joint stiffness, local swelling, skin ulcer, incisional discharge, incisional dehiscence.
seroma, annimal jilgħaq b’mod eċċessiv iż-żona tal-inċiżjoni, għebusija tal-ġogi, nefħa lokali, ulċera tal-ġilda, tnixxija tal-inċiżjoni, l-inċiżjoni ma tagħlaqx.

potential for compromised wound healing (wound dehiscence, anastomotic leakage) has been reported with aflibercept (see section 4.8).
il-potenzjal għal fejqan kompromess tal-feriti (qsim fil-ferita, tnixxija anastomotika) kienet irrappurtata b’aflibercept (ara sezzjoni 4.8).

adverse events following such surgery and not specifically associated with the product may include wound infection, osteomyelitis, mechanical complications of mechanical support, hematoma, dehiscence, nausea, fever and pain.
episodji avversi wara tali operazzjoni u li mhumiex assoċjati b’ mod speċifiku mal- prodott għandhom mnejn jinkludu infezzjoni tal- ferita, ostejomijeliti, komplikazzjonijiet mekkanikali tas- sapport mekkanikali, ematoma, dejisċenza, tqallih, deni u wġigħ.

impaired healing following transplant surgery has been reported, including fascial dehiscence, incisional hernia, and anastomotic disruption (e. g. wound, vascular, airway, ureteral, biliary).
25 fejqan imdgħajjef wara kirurġija ta ’ trapjant ġiet irrapportata, inklużi ftuħ tal- faxxa, ftuq inċiżjonali u sfaxxar tal- anastomożi (eż. ferita, vaskulari, passaġġi tal- arja, uretrali, biljari).